ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements with these filters
Aspira Pathlab approved its audited standalone financial results for the year ended March 31, 2026. The board also appointed new management and an internal auditor.
Aspira Pathlab & Diagnostics scheduled a board meeting on May 23, 2026. Directors will consider audited financial results for the quarter and year ended March 2026.
Aspira Pathlab & Diagnostics Ltd informed BSE that it does not qualify as a Large Corporate for FY 2025-26 under SEBI criteria. Consequently, the mandatory requirement to raise 25% of incremental borrowings through debt securities is not applicable. The company reported nil incremental borrowing and nil debt security issuance for the period.
Aspira Pathlab & Diagnostics Limited confirmed it is not identified as a Large Corporate as of March 31, 2026. The company reported zero outstanding borrowings and filed the disclosure in compliance with SEBI debt-raising norms for large entities.
Aspira Pathlab & Diagnostics Ltd's Independent Director Committee has recommended an Open Offer for the acquisition of 26,76,180 shares (26% stake) at ₹55 per share. The ₹14.72 Crore offer is led by Mr. Arvind Karsandas Bhanushali and others. The IDC considers the offer fair and reasonable based on SEBI valuation parameters.
Arvind Karsandas Bhanushali and others have launched an open offer to acquire a 26% stake in Aspira Pathlab & Diagnostics Limited at ₹55 per share. The total offer size is ₹14.72 Crore. The tendering period is scheduled from April 15 to April 28, 2026, following a substantial acquisition and change in control.